CHP Dosimetry

CHP Dosimetry provides advanced dosimetry solutions for the medical and radiation therapy sectors, focusing on high-precision dosimeters and calibration services essential for accurate radiation measurement and treatment planning. Founded in 2007 and headquartered in Clinton, US, CHP Dosimetry specializes in dosimetry solutions for healthcare. In November 2021, the company was acquired by Mirion Technologies, Inc. The deal was backed by major investors including Goldman Sachs Merchant Banking Division, Neuberger Berman, Fidelity Investments, BlackRock, and Janus Henderson Investors.

CHP Dosimetry specializes in advanced dosimetry solutions designed primarily for the medical and radiation therapy sectors. The company's core product offerings include high-precision dosimeters and calibration services that facilitate accurate radiation measurement and treatment planning. These products are integral to ensuring patient safety and treatment efficacy in environments such as hospitals, clinics, and research facilities. The end users of CHP Dosimetry's technology include radiation oncologists, medical physicists, and healthcare institutions globally, with a focus on markets in North America, Europe, and Asia.

By delivering state-of-the-art dosimetry tools and expertise, CHP aims to address critical challenges in radiation therapy, enhancing patient care and optimizing treatment outcomes. CHP Dosimetry generates revenue through a combination of direct sales and service agreements with healthcare providers and institutions. The company engages in B2B transactions, supplying its flagship products and calibration services to hospitals and clinics, which often require ongoing support and maintenance. Pricing structures typically involve one-time purchase agreements for dosimeters, supplemented by recurring service fees for calibration and technical support.

This model fosters long-term relationships with clients, ensuring they have reliable access to critical dosimetry solutions. The strategic approach to revenue generation allows CHP to maintain a steady flow of income while providing essential tools that enhance the quality of radiation therapy. Following its acquisition in November 2021, CHP Dosimetry aims to leverage new resources for future growth. The company plans to expand its product line, developing innovative dosimetry tools tailored for upcoming regulatory standards in radiation therapy.

Furthermore, CHP is targeting expansion into Asian markets by 2023, seeking to enhance its international presence. The recent funding from the acquisition deal will be utilized to support these initiatives, ensuring the company remains at the forefront of dosimetry solutions.